Evidence map›Paper›PMID 32676169›Full record

ArticleOncotarget2020

Correction: Bushen-Yizhi formula ameliorates cognitive dysfunction through SIRT1/ER stress pathway in SAMP8 mice.

Shi-Jie Zhang, Ting-Ting Xu, Lin Li, Yu-Min Xu, Zi-Ling Qu, Xin-Chen Wang, Shui-Qing Huang, Yi Luo, Na-Chuan Luo, Ping Lu and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Shi-Jie Zhang *Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Ting-Ting Xu *Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Lin LiInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Yu-Min XuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Zi-Ling QuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Xin-Chen WangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Shui-Qing HuangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Yi LuoInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Na-Chuan LuoInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Ping LuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Ya-Fei ShiInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Xin YangDepartment of Pharmacy, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China.
Qi WangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.17638.].

Identifiers

PMID32676169
PMCPMC7343635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.